Kinarus Therapeutics Holding AG Share Price

CURE

CH0009115129

Market Closed - Swiss Exchange 09:06:27 18/09/2026 pm IST			5-day change	1st Jan Change
20.20 ^CHF	+6.88%		+3.86%	+25.25%

26/24/26	Kinarus Therapeutics Completes Merger with Unit, Rebrands as Curatis	MT
25/24/25	Curatis AG completed the acquisition of Kinarus Therapeutics Holding AG for CHF 18.3 million in a reverse merger transaction.	CI

Valuation: Kinarus Therapeutics Holding AG

Market Cap	47.17L 57.35L 49.94L 42.82L 80.2L 55Cr 80.52L 5.64Cr 2.18Cr 28Cr 2.16Cr 2.11Cr 90Cr	P/E 2022	-0.23x	P/E 2023	-0.01x
Enterprise Value	47.08L 57.24L 49.85L 42.74L 80.05L 55Cr 80.36L 5.63Cr 2.17Cr 28Cr 2.15Cr 2.1Cr 90Cr	EV / Sales 2022	43,18,722x	EV / Sales 2023	-
Free-Float	-	Yield 2022 *	-	Yield 2023	-

* Estimated data More valuation ratios

Chart: Kinarus Therapeutics Holding AG

Dynamic Chart

Latest news: Kinarus Therapeutics Holding AG

26/24/26	Kinarus Therapeutics Completes Merger with Unit, Rebrands as Curatis	MT
25/24/25	Curatis AG completed the acquisition of Kinarus Therapeutics Holding AG for CHF 18.3 million in a reverse merger transaction.	CI
28/24/28	Swiss Exchange Regulator Drops Inquiry Into Kinarus Therapeutics	MT
06/24/06	Kinarus Therapeutics Receives Swiss Court Approval for Revocation of Bankruptcy	MT
29/24/29	Kinarus Therapeutics Shares Surge on Combination Deal With Curatis	MT
29/24/29	Curatis AG entered into a transaction agreement to acquire Kinarus Therapeutics Holding AG in a reverse merger transaction.	CI
25/23/25	Kinarus Therapeutics to File for Bankruptcy After Funding Efforts Fail	MT
31/23/31	Kinarus Therapeutics' H1 Loss Widens	MT
28/23/28	Kinarus Therapeutics Sells License for Lung Disease Treatment to Shareholder Group	MT
25/23/25	Kinarus Therapeutics Holding AG Signs Licensing Agreement to Extend Cash for Operations	CI
12/23/12	Kinarus Therapeutics’ Interim CFO Steps Down	MT
12/23/12	Kinarus Therapeutics Announces Personnel Changes	CI
27/23/27	Kinarus Therapeutics Secures Liquidity via Subordinated Bridge Loan Deals	MT

More news

Press Releases: Kinarus Therapeutics Holding AG

26/24/26	Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed	EQ
17/24/17	Kinarus Therapeutics : Q&A on the Reverse Share Split	PU
17/24/17	Kinarus Therapeutics : Q&A on the Reverse Share Split” unter Financial News / Corporate News ablegen	PU
17/24/17	Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split	EQ
01/24/01	Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis	EQ

More press releases

News in other languages: Kinarus Therapeutics Holding AG

26/24/26	Bourse Zurich: le SMI se maintient dans le vert avant l'inflation US
26/24/26	Bourse Zurich: rebond dans les premiers échanges, l'inflation US attendue
26/24/26	Bourse Zurich: un rebond escompté en entame de séance
26/24/26	Curatis (Kinarus) à l'aube de son premier jour de négoce
17/24/17	Bourse Zurich: les indices effacent une partie des pertes de la veille

More news

Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.

Employees

Sector

More about the company

Quotes

Date	Price	Change
18/26/18	CHF 20.20	+6.88%
17/26/17	CHF 18.90	+5.59%
16/26/16	CHF 17.90	-5.79%
15/26/15	CHF 19.00	-2.31%
14/26/14	CHF 19.45	0.00%

Delayed Quote Swiss Exchange

More quotes

3 years	0.9	33.15
5 years	0.9	230.27
10 years	0.9	230.27

	2022	2023
Net sales	3.34 4.06 3.53 3.03 5.67 389.01 5.69 39.86 15.41 197.69 15.24 14.9 636.59	-
Net income	-3.47Cr -4.22Cr -3.68Cr -3.15Cr -5.91Cr -405.01Cr -5.93Cr -42Cr -16Cr -205.82Cr -16Cr -16Cr -662.77Cr	-4.94Cr -6Cr -5.23Cr -4.48Cr -8.4Cr -575.81Cr -8.43Cr -59Cr -23Cr -292.62Cr -23Cr -22Cr -942.28Cr
Net Debt	16.58L 20.16L 17.56L 15.05L 28.19L 19Cr 28.3L 1.98Cr 76.58L 9.83Cr 75.76L 74.07L 32Cr	-9T -10.94T -9.53T -8.17T -15.3T -10.49L -15.36T -1L -41.57T -5L -41.12T -40.21T -17.17L

Kinarus Therapeutics Holding AG Share Price

Stocks

CURE

CH0009115129

Valuation: Kinarus Therapeutics Holding AG

Chart: Kinarus Therapeutics Holding AG

Latest news: Kinarus Therapeutics Holding AG

Press Releases: Kinarus Therapeutics Holding AG

News in other languages: Kinarus Therapeutics Holding AG

Quotes and Performance

Price Extremes

Financials

Company Profile

Quotes

1 day	+6.88%
Current month	+25.25%
Current year	+25.25%